Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | CCKAR | P32238 | 4/20 | 0.50 |
| ▸ | CCKBR | P32239 | 4/20 | 0.50 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.50 |
| ▸ | APC | P25054 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630662 | 0.96 | NAALAD2 (0.58) | NAALAD2OPRD1OPRM1OPRK1ENPEP | |
| SCHEMBL29695538 | 0.89 | NAALAD2 (0.52) | NAALAD2OPRD1OPRM1OPRK1CCKAR | |
| SCHEMBL30547470 | 0.87 | OPRD1 (0.54) | OPRD1OPRM1OPRK1CCKARCCKBR | |
| SCHEMBL29540311 | 0.87 | NAALAD2 (0.59) | NAALAD2OPRD1OPRM1OPRK1ENPEP | |
| SCHEMBL1370956 | 0.87 | NAALAD2 (0.52) | NAALAD2OPRD1OPRM1OPRK1APC | |
| SCHEMBL1374034 | 0.87 | NAALAD2 (0.52) | NAALAD2OPRD1OPRM1OPRK1APC | |
| SCHEMBL30844088 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1OPRK1CCKARCCKBR | |
| SCHEMBL30898605 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL31615028 | 0.86 | NAALAD2 (0.65) | NAALAD2ENPEP | |
| SCHEMBL30584641 | 0.85 | OPRD1 (0.55) | NAALAD2OPRD1OPRM1OPRK1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022193902-A1 | CYCLIC COMPOUND LIBRARY AND CONSTRUCTION METHOD THEREFOR | 亚飞上海生物医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |